β受体阻滞剂-话题@MedSci

#β受体阻滞剂#

106篇内容 | 1965人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1274992, encodeId=1f9112e49928b, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Med Sci：提高β受体阻滞剂的剂量可减少与心力衰竭有关的住院和心律失常事件, objectType=article, longId=190425, objectId=b42d19042540, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b42d19042540, replyNumber=0, likeNumber=40, createdTime=2020-03-21, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b42d19042540, moduleTitle=Med Sci：提高β受体阻滞剂的剂量可减少与心力衰竭有关的住院和心律失常事件, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b42d19042540)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274991, encodeId=69c812e499120, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=BMC Cardiovasc Disord：慢性心力衰竭和心房纤颤患者的β受体阻滞剂和全因死亡风险, objectType=article, longId=190417, objectId=8aca19041e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8aca19041e2b, replyNumber=0, likeNumber=25, createdTime=2020-03-21, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8aca19041e2b, moduleTitle=BMC Cardiovasc Disord：慢性心力衰竭和心房纤颤患者的β受体阻滞剂和全因死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8aca19041e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274990, encodeId=8c7f12e4990cf, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=J Hepatology：心功能，难治性腹水和β受体阻滞剂对肝硬化患者肝移植预后的影响, objectType=article, longId=190081, objectId=8a911900817c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a911900817c, replyNumber=0, likeNumber=33, createdTime=2020-03-18, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a911900817c, moduleTitle=J Hepatology：心功能，难治性腹水和β受体阻滞剂对肝硬化患者肝移植预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a911900817c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274989, encodeId=a1e512e4989af, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=“BETA”原则：冠心病患者如何使用β受体阻滞剂, objectType=article, longId=189561, objectId=8390189561b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8390189561b2, replyNumber=0, likeNumber=33, createdTime=2020-03-10, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8390189561b2, moduleTitle=“BETA”原则：冠心病患者如何使用β受体阻滞剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8390189561b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274988, encodeId=b8f712e498812, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%, objectType=article, longId=186169, objectId=d65f1861694f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d65f1861694f, replyNumber=0, likeNumber=31, createdTime=2020-01-14, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d65f1861694f, moduleTitle=中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d65f1861694f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274987, encodeId=22e312e4987b9, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=JAMA Netw Open:中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%, objectType=article, longId=186120, objectId=462318612022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=462318612022, replyNumber=0, likeNumber=34, createdTime=2020-01-13, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=462318612022, moduleTitle=JAMA Netw Open:中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=462318612022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274986, encodeId=59f312e4986b1, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=JACC：β受体阻滞剂可降低心衰伴射血分数降低患者的死亡风险, objectType=article, longId=184381, objectId=81dd184381f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81dd184381f4, replyNumber=0, likeNumber=46, createdTime=2019-12-09, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81dd184381f4, moduleTitle=JACC：β受体阻滞剂可降低心衰伴射血分数降低患者的死亡风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81dd184381f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274985, encodeId=2ab712e4985b9, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Crit Care：发病前β受体阻滞剂暴露与脓毒症死亡率之间的关联, objectType=article, longId=179821, objectId=27381e98217d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=27381e98217d, replyNumber=0, likeNumber=35, createdTime=2019-09-23, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=27381e98217d, moduleTitle=Crit Care：发病前β受体阻滞剂暴露与脓毒症死亡率之间的关联, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=27381e98217d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274984, encodeId=35d912e4984ae, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=β受体阻滞剂治疗高血压的临床应用建议, objectType=article, longId=177194, objectId=81581e7194c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=81581e7194c3, replyNumber=0, likeNumber=23, createdTime=2019-08-09, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=81581e7194c3, moduleTitle=β受体阻滞剂治疗高血压的临床应用建议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=81581e7194c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274983, encodeId=73dd12e498366, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=JACC：ACEI和β受体阻滞剂能减少化疗乳腺癌患者的心脏毒性, objectType=article, longId=168960, objectId=a861168960b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a861168960b7, replyNumber=0, likeNumber=38, createdTime=2019-06-24, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a861168960b7, moduleTitle=JACC：ACEI和β受体阻滞剂能减少化疗乳腺癌患者的心脏毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a861168960b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274982, encodeId=ee9e12e498247, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=2019年美国胸科协会年会：β受体阻滞剂可降低肺移植后房颤的发生率, objectType=article, longId=166800, objectId=cf8f166800fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8f166800fa, replyNumber=0, likeNumber=34, createdTime=2019-05-27, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8f166800fa, moduleTitle=2019年美国胸科协会年会：β受体阻滞剂可降低肺移植后房颤的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf8f166800fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274981, encodeId=6ad012e49812c, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=β受体阻滞剂在高血压应用中的专家共识, objectType=article, longId=165739, objectId=3a78165e3980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a78165e3980, replyNumber=0, likeNumber=22, createdTime=2019-05-10, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a78165e3980, moduleTitle=β受体阻滞剂在高血压应用中的专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a78165e3980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274980, encodeId=728012e498002, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=2019版《β受体阻滞剂在高血压应用中的专家共识》在京发布, objectType=article, longId=162908, objectId=a3c81629085d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3c81629085d, replyNumber=0, likeNumber=31, createdTime=2019-03-26, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3c81629085d, moduleTitle=2019版《β受体阻滞剂在高血压应用中的专家共识》在京发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3c81629085d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274979, encodeId=b6e912e4979f9, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=AP&T：非选择性β受体阻滞剂增加肝硬化患者门静脉血栓形成的概率, objectType=article, longId=160232, objectId=cfc5160232ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cfc5160232ec, replyNumber=0, likeNumber=36, createdTime=2019-02-18, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cfc5160232ec, moduleTitle=AP&T：非选择性β受体阻滞剂增加肝硬化患者门静脉血栓形成的概率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cfc5160232ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274978, encodeId=864412e4978aa, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Eur Heart J：β受体阻滞剂、钙拮抗剂与稳定性冠状动脉疾病患者死亡率的关系, objectType=article, longId=157152, objectId=5a6115e152ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a6115e152ee, replyNumber=0, likeNumber=28, createdTime=2019-01-02, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a6115e152ee, moduleTitle=Eur Heart J：β受体阻滞剂、钙拮抗剂与稳定性冠状动脉疾病患者死亡率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a6115e152ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274977, encodeId=dc1612e497729, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Clin Res Cardiol：β受体阻滞剂与慢性心力衰竭——达到“目标剂量”还是“目标心率”？, objectType=article, longId=154613, objectId=fd541546136d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fd541546136d, replyNumber=0, likeNumber=32, createdTime=2018-11-30, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fd541546136d, moduleTitle=Clin Res Cardiol：β受体阻滞剂与慢性心力衰竭——达到“目标剂量”还是“目标心率”？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fd541546136d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274976, encodeId=f24812e497624, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=J Aller Cl Imm-Pract：过敏反应与服用β受体阻滞剂和血管紧张素转换酶抑制剂的关系, objectType=article, longId=152882, objectId=97e515288294, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97e515288294, replyNumber=0, likeNumber=31, createdTime=2018-11-08, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97e515288294, moduleTitle=J Aller Cl Imm-Pract：过敏反应与服用β受体阻滞剂和血管紧张素转换酶抑制剂的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97e515288294)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274975, encodeId=73f712e497525, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Am J Cardiol：心衰患者用>25 mg/d的β受体阻滞剂降低死亡率, objectType=article, longId=151198, objectId=77581511982e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77581511982e, replyNumber=0, likeNumber=21, createdTime=2018-10-18, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77581511982e, moduleTitle=Am J Cardiol：心衰患者用>25 mg/d的β受体阻滞剂降低死亡率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77581511982e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274974, encodeId=91d912e49744f, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Ann Intern Med：β受体阻滞剂在孕妇中的使用情况和先天性畸形的风险, objectType=article, longId=151179, objectId=10aa1511e908, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10aa1511e908, replyNumber=0, likeNumber=27, createdTime=2018-10-18, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10aa1511e908, moduleTitle=Ann Intern Med：β受体阻滞剂在孕妇中的使用情况和先天性畸形的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10aa1511e908)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1274973, encodeId=aa4012e497364, content=<a href='/topic/show?id=338c19228b0' target=_blank style='color:#2F92EE;'>#β受体阻滞剂#</a>, objectTitle=Brit J Surg：β受体阻滞剂治疗对急诊结肠癌术后早期死亡率的影响, objectType=article, longId=150404, objectId=af2015040478, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af2015040478, replyNumber=0, likeNumber=39, createdTime=2018-10-07, rootId=0, userName=muzishouyi, userId=685a124, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af2015040478, moduleTitle=Brit J Surg：β受体阻滞剂治疗对急诊结肠癌术后早期死亡率的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af2015040478)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

β受体阻滞剂

2020-05-29

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Med Sci：提高β受体阻滞剂的剂量可减少与心力衰竭有关的住院和心律失常事件

2020-03-21

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

BMC Cardiovasc Disord：慢性心力衰竭和心房纤颤患者的β受体阻滞剂和全因死亡风险

2020-03-21

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

J Hepatology：心功能，难治性腹水和β受体阻滞剂对肝硬化患者肝移植预后的影响

2020-03-18

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

“BETA”原则：冠心病患者如何使用β受体阻滞剂

2020-03-10

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%

2020-01-14

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

JAMA Netw Open:中国仅14.8%心衰患者出院时处方β受体阻滞剂！首次中国心衰医疗质量评估：出院时预约随访比例仅11.8%

2020-01-13

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

JACC：β受体阻滞剂可降低心衰伴射血分数降低患者的死亡风险

2019-12-09

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Crit Care：发病前β受体阻滞剂暴露与脓毒症死亡率之间的关联

2019-09-23

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

β受体阻滞剂治疗高血压的临床应用建议

2019-08-09

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

JACC：ACEI和β受体阻滞剂能减少化疗乳腺癌患者的心脏毒性

2019-06-24

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

2019年美国胸科协会年会：β受体阻滞剂可降低肺移植后房颤的发生率

2019-05-27

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

β受体阻滞剂在高血压应用中的专家共识

2019-05-10

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

2019版《β受体阻滞剂在高血压应用中的专家共识》在京发布

2019-03-26

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

AP&T：非选择性β受体阻滞剂增加肝硬化患者门静脉血栓形成的概率

2019-02-18

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Eur Heart J：β受体阻滞剂、钙拮抗剂与稳定性冠状动脉疾病患者死亡率的关系

2019-01-02

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Clin Res Cardiol：β受体阻滞剂与慢性心力衰竭——达到“目标剂量”还是“目标心率”？

2018-11-30

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

J Aller Cl Imm-Pract：过敏反应与服用β受体阻滞剂和血管紧张素转换酶抑制剂的关系

2018-11-08

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Am J Cardiol：心衰患者用>25 mg/d的β受体阻滞剂降低死亡率

2018-10-18

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Ann Intern Med：β受体阻滞剂在孕妇中的使用情况和先天性畸形的风险

2018-10-18

muzishouyi (审核中...)

前往app查看评论内容

#β受体阻滞剂#

Brit J Surg：β受体阻滞剂治疗对急诊结肠癌术后早期死亡率的影响

2018-10-07

科室
- - 订阅+
  - 更多科室
工具
服务